Boyers, Dwayne; Jia, Xueli; Jenkinson, David; Mowatt, Graham - In: PharmacoEconomics 30 (2012) 6, pp. 483-495
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of eltrombopag (GlaxoSmithKline) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of patients with chronic immune or idiopathic thrombocytopenic purpura (ITP), as...